HCG Injections: Uses, Dosage, and Complete Guide
HCG has established fertility and endocrine uses, plus emerging applications alongside or after testosterone treatment. This guide separates those settings, explains what the studies measured, and covers product-specific dosing context, injection routes, storage and monitoring.
What Is HCG and Where Does It Come From?
HCG supports the corpus luteum in early pregnancy. Prescription forms include urine-derived HCG, such as Pregnyl, and recombinant choriogonadotropin alfa, such as Ovidrel. They differ in presentation, approved uses and instructions; research-use material is not another interchangeable clinical formulation.
HCG activates the LH/hCG receptor. In males this can stimulate Leydig-cell testosterone production; in female fertility care it can trigger final follicular maturation and ovulation after appropriate stimulation. Sources: Pregnyl US prescribing information; Ovidrel US labeling.
IU describes biological activity, not liquid volume. There is no universal 5,000 IU/mL concentration. For arithmetic only, 0.1 mL of a solution confirmed to contain 5,000 IU/mL contains 500 IU. That calculation does not select a dose or injection route.
How HCG Works: Mechanism of Action in Males
The hypothalamus releases GnRH; the pituitary releases LH and FSH. LH supports Leydig-cell testosterone production, while FSH acts on Sertoli cells involved in sperm development. External testosterone can suppress these signals through feedback.
HCG supplies an LH-like signal at the testis. It does not directly restart hypothalamic GnRH or pituitary LH/FSH secretion, and it is not a replacement for FSH in every fertility condition. A normal serum testosterone result can coexist with impaired sperm production.
Medical Uses of HCG
Pregnyl includes selected male hypogonadotropic hypogonadism and certain female ovulation-induction uses. Primary testicular failure, including many cases of Klinefelter syndrome, is different: raising the LH-like signal may have limited effect when the testis cannot respond. Pregnyl US prescribing information; AUA/ASRM male-infertility guideline.
Male fertility treatment may combine HCG with FSH or menotropins when appropriate. The aim and monitoring differ from an off-label add-on to testosterone; HCG is not an essential component of every TRT prescription.
The AUA cryptorchidism guideline recommends against hormones to induce testicular descent because response and lasting efficacy are limited, despite the older indication remaining in Pregnyl labeling. Specialist assessment should not be delayed.
HCG is not an established weight-loss treatment. The related HCG-diet topic should be distinguished from its fertility uses.
HCG and Testosterone Replacement Therapy: Testicular Preservation
Coviello and colleagues’ 2005 randomized study assigned 29 healthy men to testosterone plus placebo or 125, 250 or 500 IU HCG every other day for three weeks. HCG supported intratesticular testosterone in a dose-dependent fashion. This measured a hormonal endpoint, not long-term fertility or pregnancy.
Hsieh and colleagues’ 2013 retrospective series followed 26 men on TRT plus 500 IU intramuscular HCG every other day. No participant became azoospermic, and nine contributed to a partner pregnancy; mean follow-up was 6.2 months. Encouraging results from a small uncontrolled series cannot guarantee preservation for every man.
AUA/ASRM male-infertility guideline emphasizes counseling about testosterone-related sperm suppression and considers the evidence for adding HCG to preserve fertility too limited for a routine recommendation. Near-term family-building plans deserve a fertility-focused discussion before testosterone treatment. Recovery after stopping testosterone varies and can be prolonged.
Standard HCG Dosing Protocols
Regimens must be interpreted in context: labeled hypogonadotropic-hypogonadism treatment, a short mechanistic study and off-label TRT support answer different questions. More HCG does not automatically mean better sperm production.
Figures such as 250–500 IU two or three times weekly, 250 IU daily, and 500–1,000 IU every third day circulate in TRT discussions. They are not a single validated standard, and schedules with similar injection sizes can deliver substantially different weekly exposure. The original research above should not be converted into a self-directed escalation plan.
For one labeled male hypogonadotropic-hypogonadism regimen, Pregnyl describes 500–1,000 USP units three times weekly for three weeks, then the same dose twice weekly for three weeks. Its label also lists longer regimens for selected cases. These are clinician-managed indication-specific examples, not a TRT or post-cycle prescription. Pregnyl US prescribing information.
Do not increase HCG based solely on perceived shrinkage or semen volume. The dose, route and follow-up depend on diagnosis, testosterone/estradiol response, semen results when relevant, and adverse effects.
Subcutaneous vs Intramuscular HCG Administration
US Pregnyl is labeled for intramuscular use. Ovidrel is supplied as a 250-microgram single-use subcutaneous syringe for female fertility treatment. Do not exchange products, routes or microgram/IU doses using a generic conversion. Pregnyl US prescribing information; Ovidrel US labeling.
Jones and colleagues’ 1994 study compared intramuscular administration in the first week with subcutaneous administration in the second in eight patients with hypogonadotropic hypogonadism. Testosterone responses were comparable and patients accepted self-injection well. This small, sequential comparison supports a possible clinical option, not universal route superiority.
For a clinician-prescribed subcutaneous regimen, obtain training for the exact product and equipment: hand hygiene, site cleaning, the appropriate tissue depth, site rotation and sharps disposal. Needle length, angle and volume are not fixed for every person. Intramuscular administration does not inherently require more liquid; concentration and prescribed dose determine volume.
HCG Side Effects and Risk Management
Reported effects include local reactions, headache, mood symptoms, fluid retention and occasional gynecomastia. Severe allergy is possible. Ovarian hyperstimulation syndrome can occur in prescribed fertility treatment, not just misuse. Pregnyl US prescribing information.
New breast symptoms or acne during hormone treatment merit assessment; automatic anastrozole or letrozole is not a universal prevention strategy. Estradiol has normal physiological roles, and treatment should follow symptoms and appropriate tests rather than a presumed need for “protection.”
If hematocrit is elevated during combined TRT/HCG use, the clinician should assess the complete regimen and contributing causes. Routine blood donation is not a substitute for evaluating the cause or deciding whether treatment needs adjustment.
Sudden severe testicular pain needs emergency assessment rather than waiting for adaptation or taking an NSAID to mask it. Severe pelvic or abdominal pain with rapid swelling, breathing difficulty or markedly reduced urination during fertility treatment also needs urgent care. Mild symptoms should be discussed if persistent or worsening.
Experience in fertility care is useful, but it does not establish the long-term safety of every high-dose combination or indefinite performance-enhancement regimen.
Storage, Reconstitution, and Handling of HCG
Pregnyl’s supplied solvent contains sodium chloride and benzyl alcohol; use the specified diluent and pharmacy instructions. Store unopened product at 15–25°C; reconstituted product at 2–8°C, discarding after 60 days. Do not freeze or shake. Pregnyl US prescribing information.
Ovidrel is already a solution, not a powder requiring reconstitution. It is refrigerated at 2–8°C; patients may keep it at up to 25°C for no more than 30 days and must use it within that period. Protect it from light in the original package and discard unused material after its single use. Ovidrel US labeling.
Arithmetic example, not a mixing instruction: a vial containing 5,000 IU in a confirmed final volume of 1 mL has a concentration of 5,000 IU/mL; 0.1 mL contains 500 IU. The amount of diluent added and the final concentration must match the actual product directions. HCG IU are not insulin-syringe “units”: on a U-100 scale, the 10-unit mark represents 0.1 mL, not 10 IU of HCG.
Use a new sterile needle and syringe each time; do not share single-patient vials. Follow the earlier applicable expiration or pharmacy beyond-use instruction. A clear-looking solution can still be contaminated, and a supplier’s generic storage claim cannot establish the sterility or clinical shelf life of a research vial.
Where to Source HCG: Legal and Quality Considerations
For treatment, use a licensed clinician and dispensing pharmacy. Ask which product is supplied, why it was selected, its prescribed route, storage rules and follow-up needs. An off-label prescription is distinct from purchasing material labeled “not for human use.”
FDA’s HCG information identifies approved products as prescription injections, not over-the-counter weight-loss products. Research labels, online testimonials and HPLC purity certificates do not establish injectable sterility, endotoxin control or appropriate clinical use.
For cost, obtain a current quote for the exact product and quantity, then account for the prescribed regimen and usable vial life. Include consultation, laboratory, supplies and delivery charges where applicable. Insurance, GoodRx discounts and assistance eligibility vary; a fixed monthly range or a research-supplier price is not a reliable treatment-cost comparison.
HCG Monitoring and Assessment of Effectiveness
Monitoring should answer the treatment goal. Testosterone and other relevant hormone tests help assess endocrine response; semen analysis assesses sperm parameters when fertility matters. Serum testosterone during TRT cannot isolate how much testosterone the testes are producing.
Testicular size and ejaculate volume can be discussed with the clinician, but neither proves adequate sperm count, motility or fertility. A change is not an instruction to increase HCG. Even semen parameters do not guarantee conception, which involves both partners and other factors.
LH and FSH may remain suppressed during TRT/HCG. Tell the laboratory about HCG because some gonadotropin assays can cross-react. After stopping anabolic steroids or testosterone, persistent suppression requires assessment of the full history rather than a fixed four- or eight-week test of whether HCG “preserved” the testis.
HCG and Fertility: Maximizing Sperm Production
HCG can support fertility in selected men with gonadotropin deficiency; some require FSH-containing treatment as well. Optimizing treatment means identifying the cause and following semen response, not maximizing the HCG dose.
The AUA/ASRM guideline supports individualized endocrine treatment for infertile men with low testosterone, with limited-quality evidence for several options. Primary testicular failure and pituitary disease can change which treatments are likely to work.
Sperm development and recovery take time. Changes may take months, and the timing of repeat semen tests should reflect the diagnosis and treatment plan. An eight- or twelve-week target is not a promise of recovery or a universal deadline for starting treatment before conception.
Discuss nutrition, smoking, alcohol, heat exposure and other modifiable factors as part of fertility care. Routine zinc, selenium or antioxidant supplements are not a proven way to amplify HCG benefits in everyone.
Post-Cycle Recovery Protocols with HCG
HCG may be considered in supervised treatment after anabolic-androgenic steroid use, but it stimulates the testis rather than directly restarting pituitary LH/FSH. Recovery varies with prior exposure, baseline function and other factors. There is no universal instruction to start three to five days before stopping testosterone or use high daily doses for two to four weeks.
İbis and colleagues’ 2026 report, published online in 2025, retrospectively compared 79 men after no more than six months of steroid use, with documented normal pre-cycle hormones and semen. Treated groups recovered sooner; at 12 months, the study reported normozoospermia in 87.5% with clomiphene plus HCG, 69.2% with clomiphene and 58.6% with observation. This semen endpoint is not a pregnancy or live-birth rate.
This is promising emerging evidence, not a randomized trial or proof of an HCG-alone effect. Treatment selection, additional FSH in some patients and the selected population limit generalization. It does not establish a guaranteed four- to eight-week recovery or justify copying a post-cycle drug combination without assessment.
Persistent low-testosterone symptoms, infertility concerns or significant mood changes after stopping steroids warrant medical support. A clinician can distinguish ongoing suppression from other causes and discuss monitoring or treatment options.
HCG Comparison to Other Testicular Preservation Approaches
HCG acts at the testis; SERMs such as clomiphene or tamoxifen act through central estrogen feedback; aromatase inhibitors alter estrogen formation. They are different tools, not interchangeable protection against suppression from any testosterone regimen.
The AUA/ASRM guideline allows selected use of these agents, alone or combined, for infertile men with low testosterone, while noting limited evidence. A SERM may be ineffective in primary pituitary dysfunction; a high LH from primary testicular failure can indicate limited response to stimulation.
Calling one approach universally superior obscures the diagnosis and goal. Choose between fertility-focused treatment, testosterone therapy and other options through shared clinical decision-making, with semen testing and follow-up where relevant.
Related Guides
Frequently Asked Questions
HCG is a pregnancy-associated hormone with LH-like activity. Prescription products include urine-derived chorionic gonadotropin and recombinant choriogonadotropin alfa. In males, HCG can stimulate Leydig-cell testosterone production; that response does not by itself establish normal sperm production or fertility. Its medical use depends on the diagnosis and product.
Testosterone treatment can suppress LH, FSH and sperm production. HCG bypasses the LH signal and can maintain intratesticular testosterone. Small studies report encouraging semen findings during combined treatment, but HCG does not guarantee fertility, prevent every case of atrophy, or restore pituitary function. Discuss family-building plans before starting testosterone and use semen testing when fertility is the goal.
There is no single standard TRT or post-cycle HCG regimen. A three-week study in 29 healthy men used 125, 250 or 500 IU every other day with testosterone and measured intratesticular testosterone, not pregnancy. Labeled treatment for selected hypogonadotropic hypogonadism is a different setting. The prescriber selects the regimen from the diagnosis, product and measured response; testicular size or ejaculate volume alone should not drive dose increases.
The route depends on the product and prescription. US Pregnyl is labeled for intramuscular use; Ovidrel is a single-use subcutaneous product for female fertility treatment. Subcutaneous HCG has also been studied in males, with comparable testosterone responses in a small study, but that does not make every formulation interchangeable or establish universal superiority. Confirm the route and receive product-specific training.
Yes. Reported effects include injection-site reactions, headache, mood symptoms, fluid retention and gynecomastia. Frequency cannot be generalized to every regimen. Aromatase inhibitors are not routine protection for everyone. Ovarian hyperstimulation can occur during prescribed fertility treatment, not only misuse. Sudden severe testicular pain, severe pelvic or abdominal symptoms, breathing difficulty or a serious allergic reaction requires urgent assessment.
In the US, obtain HCG for treatment through a licensed clinician and pharmacy. A research-use label, vendor reviews or a certificate of analysis is not equivalent to a prescription product or assurance of injectable sterility. Discuss the exact product, indication, route and pharmacy instructions with the care team; off-label prescribing is distinct from buying a research chemical for self-treatment.
Ask the dispensing pharmacy for a current quote for the exact product, quantity and prescribed regimen. Monthly cost depends on dose, usable vial life, insurance and consultation or laboratory fees, so a vial price is not a monthly total. Coverage and discount eligibility vary. Research-supplier prices are not a like-for-like comparison with prescription treatment.